
A
B-ALL (n=14)
T-ALL (n=15)
AML (n=30)
CRC (n=56)
GBM (n=44)
Kidney Cancer (n=23)
DLBCL (n=17)
Plasma cell myeloma (n=25)
Melanoma (n=54)
Neuroblastoma (n=15)
OTSCC (n=29)
PAAD (n=41)
12 x 30 =360
0 20 40 60 80
% of promoters with no significant changes in mean methylation
0.8 0.6 0.4 0.2 0
PDR value


B
B-ALL (n=14)
T-ALL (n=15)
AML (n=30)
BLCA (n=24)
BRCA (n=52)
CML (n=14)
CRC (n=56)
UCEC (n=28)
ESCA (n=25)
GBM (n=44)
Kidney carcinoma (n=23)
DLBCL (n=17)
LIHC (n=23)
Hodgkin lymphoma (n=11)
Plasma cell myeloma (n=25)
SKCM (n=54)
MESO (n=10)
Neuroblastoma (n=15)
OTSCC (n=29)
OV (n=49)
PRAD (n=41)
SCLC (n=49)
THCA (n=11)
23 x 30 =690
0 25 50 75 100
% of promoters with no significant changes in mean methylation